Présentation de l'entreprise
Abeona Therapeutics Inc. operates as a commercial-stage biopharmaceutical entity dedicated to developing gene and cell therapies aimed at treating life-threatening diseases within the United States market. The company specifically focuses on the development of ZEVASKYN, an autologous, cell-based gene therapy designed for the treatment of patients suffering from recessive dystrophic epidermolysis bullosa. This organization functions within the Healthcare sector, specifically inside the Biotechnology industry, which is characterized by high research and development costs and significant regulatory hurdles before achieving commercialization. With a market capitalization of $277.83M and a workforce of 226 employees, the company maintains a relatively small operational footprint typical of early-to-mid stage biotech firms. The annual revenue of $5.82M indicates that the company is still in a growth phase where commercial sales are limited, reflecting the substantial capital required to bring specialized therapies to market rather than indicating a lack of potential.
Santé financière
The company reported a revenue of $5.82M for the trailing twelve months, yet it recorded a net income of $71.18M, creating a significant disparity that reveals a complex cost structure involving non-operating gains or specific accounting adjustments. Despite the reported net income, the EBITDA stands at $-86,899,000, highlighting that core operational profitability remains negative as the company continues to invest heavily in its pipeline. The free cash flow is reported at $-55,598,500, which signifies that the company is burning cash to fund its operations and development efforts, thereby limiting immediate financial flexibility without external capital injections. The gross margin is listed as 0.0%, suggesting that revenue recognition may not yet align with cost of goods sold in a traditional sense or that the company is in a pre-revenue or specific cost-accounting phase for its therapies. The operating margin is -422.7% and the profit margin is 1223.1%, figures that underscore the volatility inherent in biotech financial statements where non-operating items can drastically alter profit metrics compared to operational performance. The company holds $191.40M in cash against $24.97M in debt, resulting in a debt-to-equity ratio of 15.68, which presents an unusual leverage profile given the substantial cash reserves and suggests a balance sheet strategy focused on aggressive asset utilization or specific debt structuring. The current ratio of 6.93 indicates a very strong short-term liquidity position, providing ample coverage for immediate obligations despite the negative operating cash flow. Return on Equity stands at 70.0% while Return on Assets is -34.0%, metrics that reveal management's ability to generate high equity returns through non-operational means while simultaneously indicating that asset utilization is currently yielding negative returns on the balance sheet.
Évaluation de la valorisation
The stock trades with a P/E Ratio (TTM) of 4.82 and a Forward P/E of 20.29, a stark difference that implies the market expects a significant shift in earnings trajectory, potentially driven by the realization of future revenues or the reversal of current accounting anomalies. The Price to Book ratio is 1.68, indicating that the market values the company at a premium of 68% over its net asset book value, reflecting confidence in the intangible value of its pipeline and intellectual property. The Price to Sales ratio of 47.74 and an EV/EBITDA of -1.28 suggest that traditional valuation multiples are skewed by the company's unique financial situation, with the negative EV/EBITDA confirming that earnings-based valuation is currently not applicable due to losses. The 52-week high is $7.54 and the 52-week low is $3.93, placing the current market price within a specific trading range that reflects recent volatility. The Beta of 1.21 indicates that the stock price is 21% more volatile than the broader market, meaning it experiences larger swings in value during periods of market stress or rally.
Growth & Income
Revenue growth and earnings growth are both listed as N/A, preventing a direct comparison of earnings expansion relative to revenue growth within the standard historical framework. As a non-dividend payer, the company does not distribute a dividend yield or utilize a payout ratio, which explains that it reinvests all available earnings and cash reserves directly into research, development, and commercialization of its therapies rather than returning capital to shareholders. This reinvestment strategy is typical for biotechnology companies in the commercial-stage phase, where capital allocation focuses on advancing ZEVASKYN and other assets through clinical trials and regulatory approval processes. The overall growth and income profile is defined by high capital intensity and the absence of current cash distributions, relying entirely on future product commercialization to generate returns for investors.